News >

Expert Discusses De-Escalation Difficulties, Other Topics in TNBC

Shannon Connelly
Published: Sunday, Aug 13, 2017

Lisa Carey, MD
Lisa Carey, MD
The lack of nonchemotherapy options in triple-negative breast cancer (TNBC) makes it difficult to de-escalate treatment in patients with these tumors, says Lisa Carey, MD.

at the 2017 St. Gallen International Breast Cancer Conference, Carey, professor of medicine, University of North Carolina, discussed the challenges with de-escalation in patients with TNBC and steps toward overcoming these obstacles.

OncLive: Why is it difficult to de-escalate treatment for patients with TNBC?

Carey: One of the hardest places to [de-escalate treatment] is in TNBC, because we have fewer nonchemotherapy options, but there are some things that we can do. We know that the use of neoadjuvant therapy can help us minimize surgery. It’s less clear that we can use it to tailor chemotherapy, but that’s an emerging arena. It’s also true that nonrandomized studies suggest that very small node-negative TNBCs may not benefit much from chemotherapy, so we can be thoughtful about T1a/N0-type tumors and not give them chemotherapy.

I have to say that the future here [also depends on] the effective development of biomarkers to help us strategize…That includes immune biomarkers, like tumor infiltrating lymphocytes, and the incorporation of noncytotoxic options, of which we really don’t have any, but I think we are all very hopeful that we will in the near future.

Are there any biomarker-based studies currently being done?

There are a ton of biomarker-based studies. In truth, there are 2 forms of biomarker-based studies. There are integral biomarkers, where we are testing them explicitly for clinical utility. In TNBC, we don’t have any biomarkers that are ready enough that we can use them for treatment decisions. What there are a lot of are studies that are incorporating biomarkers in a testing clinical validity realm, including tumor infiltrating lymphocytes and mRNA-based gene signatures, and things to try and help with identifying patients with BRCAness and with the potential benefit of platinums. There are a lot of studies in that realm. There are none that are level 1 evidence prospective trials, but I think we will get there.

In the escalation phase, are there any agents that are promising?

The history of breast cancer therapy has been one of escalating [treatments, according to a keynote speech by Martine Piccart, MD, PhD]. We’re good at escalating. De-escalating is more challenging. Taking away things is harder to do, both from a trial design standpoint and from a funding standpoint.

TNBC is the 1 area where there is as much emphasis on escalating as there is on de-escalating, because unlike HR-positive and HER2-positive breast cancer, we haven’t had big successes in terms of our strategy. We’ve had incremental benefits, and there’s no question that patients with TNBC are doing better now than they were 10 to 20 years ago, but we still have a lot of challenges.

I would say that the escalating part is still very appropriate in TNBC, probably much more than the other clinical subsets. Within the escalating realm, there’s 2 prongs. One is taking existing drugs, cytotoxics, and applying them thoughtfully and augmenting outcomes with the addition of novel drugs between anthracyclines and taxanes. That’s where the platinum stories come in, that’s where the capecitabine and other strategies in residual disease come in.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication